Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Combination therapy for gastric mucosa-associated lymphoid tissue lymphoma

March's issue of the Alimentary Pharmacology & Therapeutics compares rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma.

News image

There is no consensus on the standard treatment of gastric mucosa-associated lymphoid tissue (MALT) lymphoma for Helicobacter pylori-negative patients and for patients with persistent disease despite H. pylori eradication.

Dr Amiot and colleagues from France evaluated the comparative efficacy and safety of alkylating agents and rituximab alone or in combination.

In this monocentric retrospective study, which included 106 patients who had not been previously treated with anti-cancer agents, the team evaluated the efficacy and safety of oral alkylating agents monotherapy, rituximab monotherapy and the therapy combining both drugs.

The researchers performed evaluations at weeks 6, 25, and 52 and after 2 years.

The 5-year progression-free survival probabilities were 89% with combination therapy
Alimentary Pharmacology & Therapeutics

After a median follow-up period of 5 years, complete remission and overall response were significantly higher in patients in the combination therapy group at week 104 compared with patients treated with alkylating agents alone, and rituximab alone.

The 5-year progression-free survival probabilities were 68%, 70% and 89% in patients treated with alkylating agents alone, rituximab alone and combination therapy respectively.

The team reported hematological adverse events in 30% of patients, and were more frequent in the two groups receiving alkylating agents.

The research team observed no toxicity-related deaths.

Dr Amiot concludes, "The use of anti-cancer systemic therapy is safe and efficient in gastric MALT lymphoma."

"In this retrospective study, the combination of rituximab plus chlorambucil seems more efficient than rituximab or alkylating agents alone."

"Rituximab has a better safety profile than regimens containing alkylating agents."

Aliment Pharmacol Ther 2014: 39(6): 619628
04 March 2014

Go to top of page Email this page Email this page to a colleague

 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 24 August 2016 
Hep B after infant vaccination program
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD
 29 July 2016 
Susceptibility loci for gallstone disease
 29 July 2016 
Tool to diagnose Helicobacter-negative gastritis
 29 July 2016 
H. pylori clarithromycin resistance in the USA
 28 July 2016 
HCV eradication in cirrhotic patients
 28 July 2016 
Hep B screening and immunosuppressive therapy
 28 July 2016 
Pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us